Understanding how anti-tuberculosis drugs work in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the pharmacokinetics of anti-tuberculosis drugs in children, hypothesizing that their drug metabolism differs from that of adults. Researchers will collect plasma samples from 100 children undergoing treatment for tuberculosis and analyze these samples using high-performance liquid chromatography. They will develop population pharmacokinetic models to assess drug concentrations and correlate these with treatment effectiveness and adverse effects. The findings are expected to enhance treatment strategies for tuberculosis in pediatric patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children (0-18 years old) with anti-tuberculosis therapy against TB.
* The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases
* Informed consent signed by the parents and/or guardians.

Exclusion Criteria:

* Anti-tuberculosis drugs aren't involved in the therapies of children.
* It is unable to provide complete medical records or the current condition cannot accept the study process.
* Patients are allergic to anti-tuberculsis drugs.
* Parents and/or guardians do not agree to participate in this study.

Where it's running

• Beijing Children's Hospital of Capital Medical University
  Beijing, China Recruiting

Study contacts

• Principal investigator: A-Dong Shen, Master — Beijing Children's Hospital of Capital Medical University
• Study coordinator: A-Dong Shen, Master
• Email: shenad16@hotmail.com
• Phone: +86-010-59616898

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Doxycycline added to standard treatment for central nervous system tuberculosis

  This trial tests whether adding doxycycline to standard anti‑TB therapy and corticosteroids helps adults with central nervous system tuberculosis live longer or have less severe neurological disability.

  Recruiting at 5 sites Phase 2 National University Hospital, Singapore · Medan, Medan and 5 other locations · NCT06446245

• Biomarker Test for Diagnosis and Monitoring of Extrapulmonary Tuberculosis

  This study tests biomarker-based methods to help diagnose extrapulmonary TB and monitor treatment in adults, including people living with HIV, using samples from affected sites in Kenya.

  Recruiting at 2 sites Nagasaki University · Nairobi and 1 other locations · NCT07901387

• Short-Course TB Treatment for Children with Non-Severe Pulmonary TB

  This trial tests two shorter-treatment options for kids with non-severe pulmonary TB to see if they can clear the infection as well as the standard 6-month plan.

  Recruiting at 13 sites Phase 2 Huashan Hospital · Fuzhou, Fujian and 12 other locations · NCT07893444

• Combined oral contraceptive timing with Ganfeborole in healthy women

  This study tests how the contraceptive Microgynon behaves in the body when given alone and with Ganfeborole in healthy women who can’t get pregnant.

  Recruiting Phase 1 GlaxoSmithKline · Madrid · NCT07784894

• Isoniazid inhalation in TB patients: a first-in-human look at local tolerability and body levels

  This early study tests inhaled isoniazid to see how well it tolerates the lungs and how it behaves in the body in adults with tuberculosis.

  Recruiting Phase 1 University Medical Center Groningen · Groningen · NCT07708779

• How the immune system responds to mycobacterial infections

  This study tests how the immune system changes in people with tuberculosis and related mycobacterial infections.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo · NCT07638670

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.